This position paper aims to provide a comprehensive analysis of the molecular mechanisms governing PD-L1 expression and to discuss emerging biomarker strategies for optimizing patient selection for checkpoint inhibitor therapy, with a particular emphasis on NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.